UK Researchers Seek to Identify Ways to Relieve Post-Chemotherapy Cognitive Impairment
Of the 14 million cancer survivors in the United States, a significant number experience a serious side effect called chemotherapy-induced cognitive impairment (CICI).
Markey and LLS Host Sixth Annual ‘Meet the Researcher Day’
UK to Announce Major Multi-million NIH Grant to Launch New Center to Fight Cancer
The University of Kentucky was recently awarded a prestigious Centers of Biomedical Research Excellence (COBRE) grant to study the metabolism of cancer from the National Institutes of General Medical Sciences, part of the National Institutes of Health. The $11.2 million grant will fund UK's Center for Cancer and Metabolism over the next five years.
NCI Director Meets with Markey Researchers, Faculty during Special Visit
Dr. Doug Lowy, interim director of the National Cancer Institute, recently visited the University of Kentucky Markey Cancer Center, continuing a dialogue on Kentucky cancer disparities following Lowy's visit to Hazard, Ky. last fall.
New Study Shows Promise for Repurposing Anti-Malarial Drug for Cancer Treatment
A new study by University of Kentucky Markey Cancer Center researchers shows that chloroquine – a drug currently used to treat malaria – may be useful in treating patients with metastatic cancers.
Expanding Precision Medicine Options, Markey Launches Molecular Tumor Board
The University of Kentucky Markey Cancer Center recently launched its own Molecular Tumor Board, an approach to cancer care that uses genetic analysis to help oncologists choose cancer therapies tailored to each patient's individual needs. The Molecular Tumor Board is the latest precision medicine initiative to come online at Markey.
Proposed Clinical Trial Could Change the Game for Deadly Type of Breast Cancer
University of Kentucky Markey Cancer Center Oncologist Dr. Edward Romond spent his career at UK treating and studying breast cancer, even leading major Phase 3 clinical trials on the breast cancer drug trastuzumab in the early 2000s. Commonly known as Herceptin, this drug became a standard of care for patients with HER2-positive breast cancer.
Markey's Miller Receives NCI Clinical Investigator Team Leadership Award
University of Kentucky Markey Cancer Center's Dr. Rachel Miller is one of 13 recipients of this year's National Cancer Institute Cancer Clinical Investigator Team Leadership Award.
Researchers Present Cancer Studies at Markey Research Day
The annual University of Kentucky Markey Cancer CenterResearch Day not only provides researchers with the opportunity to share their work, but to get feedback from colleagues. An estimated 400 people were in attendance at the event, with about 50 staff members tasked with judging posters.